Brought to you by 
EOS, Medarex develop and market antibody therapeutics
26 Jan 2001
Executive Summary
Eos (uses genomics, bioinformatics, and pathobiological processes to create therapeutic and diagnostic products) has entered into a strategic alliance with Medarex (antibody-based therapeutics) to develop and market up to six fully cloned human antibody therapeutics for cancer and other diseases.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
EOS, Medarex develop and market antibody therapeutics
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice